Sinclair Pharma PLC’s (SPH) Buy Rating Reaffirmed at N+1 Singer
Sinclair Pharma PLC (LON:SPH)‘s stock had its “buy” rating reissued by equities researchers at N+1 Singer in a research note issued to investors on Wednesday.
SPH has been the subject of several other reports. Peel Hunt reiterated a “buy” rating and set a GBX 68 ($0.89) target price on shares of Sinclair Pharma PLC in a research report on Tuesday, September 27th. Stifel Nicolaus reiterated a “buy” rating and set a GBX 49 ($0.64) target price on shares of Sinclair Pharma PLC in a research report on Thursday, September 1st. Jefferies Group dropped their target price on shares of Sinclair Pharma PLC from GBX 60 ($0.78) to GBX 55 ($0.72) and set a “buy” rating for the company in a research report on Wednesday, June 15th. Finally, Royal Bank Of Canada reiterated an “outperform” rating on shares of Sinclair Pharma PLC in a research report on Thursday, September 15th. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of GBX 57 ($0.74).
Sinclair Pharma PLC (LON:SPH) traded down 1.75% during trading on Wednesday, hitting GBX 28.00. The company’s stock had a trading volume of 955,026 shares. The firm has a 50 day moving average of GBX 28.87 and a 200 day moving average of GBX 31.96. Sinclair Pharma PLC has a 12 month low of GBX 26.00 and a 12 month high of GBX 61.33. The firm’s market cap is GBX 139.16 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/sinclair-pharma-plcs-sph-buy-rating-reaffirmed-at-n1-singer.html
In other Sinclair Pharma PLC news, insider Jeff Thompson acquired 150,000 shares of the stock in a transaction dated Tuesday, October 4th. The stock was purchased at an average cost of GBX 29 ($0.38) per share, for a total transaction of £43,500 ($56,781.10).
Sinclair Pharma PLC Company Profile
Sinclair Pharma plc, formerly Sinclair IS Pharma plc, is a United Kingdom-based specialty pharmaceutical company. The Company is engaged in the manufacture and wholesale distribution of dermatological products. Its segments are Country Operations, which include its operations in France, the United Kingdom, Italy, Germany and Spain, and International Operations, under which the Company sells through a local distributor.
Receive News & Ratings for Sinclair Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinclair Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.